Compare Amcor PLC (AMCR) vs Ginkgo Bioworks Holdings Inc (DNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amcor PLC vs Ginkgo Bioworks Holdings Inc — how do they compare? Amcor PLC trades at $46.95 (market cap $21.92B), while Ginkgo Bioworks Holdings Inc trades at $7.43 (market cap $505.73M). The key difference: Amcor PLC is far larger — about 43.3× Ginkgo Bioworks Holdings Inc's market cap, and Amcor PLC pays a 5.49% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals.
| AMCR | DNA | |
|---|---|---|
Market Cap | $21.92B | $505.73M |
Sector | Basic Materials | Health |
52-Week High | $50.58 | $16.14 |
52-Week Low | $36.69 | $5.48 |
Enterprise Value | $37.03B | $607.68M |
Dividend Yield | 5.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMCR trades at $46.85, down 0.55% today, with a bullish technical outlook supported by moving averages and strong earnings beats in the last four quarters. The company reported Q2 2026 EPS of $1.23, exceeding estimates, and maintains a 64% analyst buy rating with a $47.00 consensus target. Recent news highlights expansion in China and strong Q4 results, though net income margin declined to 3.06% in 2025.
The stock presents a balanced opportunity with solid earnings performance and analyst support, but risks include elevated P/E of 38.07, margin pressure, and high debt levels. Upside is capped near-term by technical resistance at $48, while support lies at $46.
Ginkgo Bioworks (DNA) trades at $7.29, down 4.71% with bearish technical signals. The company reported Q2 2026 revenue of $20 million, down 48% year-over-year, continuing its strategic pivot to autonomous labs. Despite beating EPS expectations in two of the last three quarters, DNA shows negative profitability with -219.6% net income margin and negative cash flow. Analyst sentiment is mixed with 45% buy ratings but significant institutional selling pressure.
DNA faces substantial execution risk during its business transition, with declining revenue and persistent losses offset by potential in autonomous laboratory technology. The stock's current valuation at 3.61x sales appears stretched given negative earnings, requiring successful operational turnaround for sustainable recovery. Near-term catalysts depend on revenue stabilization and cost management improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amcor PLC
Amcor is a global plastics packaging behemoth, with global sales of USD 14.5 billion in fiscal 2022 following the acquisition of Bemis in 2019. Amcor's operations span over 40 countries globally and include significant emerging-market exposure equating to circa 20% of sales. Amcor's capabilities span flexible and rigid plastic packaging, which sell into defensive food, beverage, healthcare, household, and personal-care end markets.
Read more on AMCR →About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →
